Vaccine Responses in Cancer (VRiC)

Abramson Cancer Center at Penn Medicine

Status: Active, not recruiting

Conditions: Viral Vaccines

Treatments: Biological: Zoster Vaccine Recombinant; Biological: Influenza vaccination; Biological: SARS-CoV-2 vaccine

Study type: Observational

Funder types: Other

Identifiers

NCT06605625

852151

UPCC27922 (Other Identifier)

Details and patient eligibility

About

The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.

Full description

Vaccinations are indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. In particular, immune responses following vaccination have not been studied in the setting of cancer and in the context of various anti-tumor treatments. In this study, the investigators will look at the immune response of subjects receiving vaccination.

Enrollment: 250 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• adults over age 18 who are able to provide consent, who have a diagnosis of cancer, and are willing to receive the influenza, recombinant shingles, and/or SARS-CoV-2 vaccines.

Exclusion criteria

• allergic to influenza, shingles, and/or SARS-CoV-2 vaccination; have HIV infection; have a history of solid organ or bone marrow transplant.

Trial design

250 participants in 1 patient group

Patients with Cancer

Description:

Patients with cancer who are clinically indicated to receive influenza, recombinant shingles and/or SARS-CoV2 vaccine

Treatment:

Biological: SARS-CoV-2 vaccine

Biological: Influenza vaccination

Biological: Zoster Vaccine Recombinant